NeuPath Health Inc. · TSXV:NPTH
NeuPath Health — Investor Presentation (September 2020)
20 slides from NeuPath Health's investor presentation, September 2020
Slide 1: Corporate Presentation September 2020
CORPORATE PRESENTATION SEPTEMBER 2020 TSXV: NPTH www.neupath.com
Slide 2: Legal Disclaimer
Legal Disclaimer Certain statements contained in this Presentation may constitute forward-looking information under the meaning of applicable securities laws, which are based on the opinions, estimates and assumptions of the NeuPath’s management and are subject to a variety of risks, uncertainties a
Slide 3: Legal Disclaimer – non-IFRS Measures
Legal Disclaimer – non-IFRS Measures Non-IFRS Measures This presentation contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as
Slide 4: Investment Highlights
Investment Highlights Large, growing Leading chronic Significant growth Integrating new and underserved pain management opportunities technologies & market company treatments • Affects 1 in 5 • Largest in Canada • Grow revenue by • Tech to improve Canadian adults almost 2x based patient outcomes • C
Slide 5: Chronic pain market
Chronic pain market $37 billion • Employers & insurance carriers Higher functioning chronic • Requires national High impact chronic pain pain patients: 15% of patients: 5% of population1 network population Work School Self-care 1 MH Pitcher et al. Prevalence and profile of High Impact Chronic Pain i
Slide 6: About NeuPath
About NeuPath • NeuPath is Canada’s largest provider of chronic pain management services • NeuPath pain clinics offer a comprehensive chronic pain assessment and multi-modal treatment plan based on recommendations by a group of trained physicians to help patients manage their chronic pain and optimi
Slide 7: Multimodal Approach
Multimodal Approach Nerve block injections & Mindfulness meditation & lidocaine infusions chronic pain self management Medical cannabis Reduction in opioid reliance 7
Slide 8: The NeuPath Advantage
The NeuPath Advantage Strategically Industry Leading Integrating New Patient-Centered, Located Clinic Training Program Tech & Clinical Data Driven Footprint Approaches Culture • Coverage of • 6-part training • Improve patient • Reduce wait times ~67% of ON program outcomes • Help more patients popul
Slide 9: Growth Strategy - Organic
Growth Strategy - Organic Improved capacity utilization with room to continue growth • Measure capacity utilization based on combination of physician shift and 60 60 patient appointment slot vacancy rates 50 50 • Capacity utilization rate has increased Revenue ($Millions) 40 40 from 29% in 2017 to 5
Slide 10: Growth Strategy – M&A
Growth Strategy – M&A Fragmented Small Groups or Reasonable Strategic Growth Market Single-Location Valuations Via Acquisitions Clinics • More than 60 • Many single- • Lack of exit • Acquire clinics and multidisciplinary location clinics opportunities leads create efficiencies clinics in Ontario wit
Slide 11: Financial Performance
Financial Performance ANNUAL RESULTS QUARTER RESULTS Revenue Adjusted EBITDA Revenue Adjusted EBITDA (CAD Millions) (CAD Millions) (CAD Millions) (CAD Millions) 60 14 1 50 2.5 12 2 10 0.8 40 1.5 8 0.6 30 1 6 20 0.4 0.5 4 10 0.2 0 2 0 2017 2018 2019 2020 -0.5 0 0 2017 2018 2019 2020 YTD Q1 Q1 Q2 Q2 Q
Slide 12: Patient Visits 2020
Patient Visits 2020 • Over 75,000 patient visits YTD • March and April patient visits were low due to COVID-19 • June and July patient visits exceeded January (the best month to date) JAN FEB MAR APR MAY JUNE JULY 12
Slide 13: Summary Capital Structure
Summary Capital Structure Fully Diluted Ownership Board & Mgmt 11% Equity Capital Structure (Millions) Funds and Other Total shares issued and outstanding 28.5 shareholders 45% Paid-up warrants1 10.4 44% Dilutive Instruments: Warrants 11.0 Stock Options 1.5 Fully-Diluted Shares 51.4 Note 1: The paid
Slide 14: Comparable Companies
Comparable Companies Share Market Cap EV CAGR - Revenue EV / Sales Company Price (C$mm, as of 2020-08-26) 1 Year 2 Year 3 Year LTM CY19 CY20e CY21e WELL Health (TSX: WELL) C$ 4.92 679.3 666.8 210.7% n.d. n.d. 17.2x n.m. 15.2x 11.0x VieMed (TSX / NASDAQ: VMD) C$ 14.57 569.5 554.4 24.5% 30.8% 36.8% 3.
Slide 15: Experienced Leadership Team
Experienced Leadership Team • Joined in July 2018 • Former CEO of VroomHealth Grant Connelly • Former CFO of Appletree Medical Group that operated over 30 medical clinics Chief Executive Officer • Over $200M in M&A transactions • MBA – Schulich School of Business at York • Joined in April 2019 • CPA
Slide 16: Board of Directors
Board of Directors Dianne Carmichael, Chair Jolyon Burton • Former President, Best Doctors Inc. • Co-founder of Bloom Burton & Co., providing capital raising, • Former President, Payer Markets at McKesson M&A advisory, equity research, business strategy & scientific • Former President, UHN Solutions
Slide 17: Investment Highlights
Investment Highlights Large, growing Leading chronic Significant growth Integrating new and underserved pain management opportunities technologies & market company clinical approaches • Affects 1 in 5 • Largest in • Grow revenue • Tech to improve Canadian adults Canada by almost 2x patient based on
Slide 18: Thank You
NeuPath Health Grant Connelly CEO [email protected] Thank You Stephen Lemieux CFO [email protected] [email protected] 18
Slide 19: Corporate Presentation
CORPORATE PRESENTATION SEPTEMBER 2020 TSXV: NPTH www.neupath.com
Slide 20: Adjusted EBITDA
Adjusted EBITDA Non-IFRS Measures EBITDA refers to net income (loss) determined in accordance with IFRS, before depreciation and amortization, net interest expense (income) and income tax expense (recovery). The Company defines adjusted EBITDA as net income from continuing operations before net inte
NeuPath Health — Investor Presentation (September 2020) on 6ix